Merck, Inc.
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06567002
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase ( Site 0001), South Miami, Florida, United States
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06566989
- Locations
- 🇬🇧
Quotient Sciences ( Site 0001), Nottingham, Nottinghamshire, United Kingdom
MSD Belzutifan PAS
- Conditions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06554730
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06554639
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06504394
- Locations
- 🇨🇱
FALP ( Site 0207), Santiago, Region M. De Santiago, Chile
🇨🇱Bradfordhill-Clinical Area ( Site 0202), Santiago, Region M. De Santiago, Chile
🇰🇷Seoul National University Hospital-Oncology ( Site 1101), Seoul, Korea, Republic of
Open-label Extension Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3000
- Registration Number
- NCT06492291
- Locations
- 🇨🇳
Zhujiang Hospital ( Site 6029), Guangzhou, Guangdong, China
🇭🇰Queen Mary Hospital-Medical ( Site 3300), Hksar, Hong Kong
🇭🇺Semmelweis Egyetem-Városmajori Szív- és Érgyógyászati Klinika ( Site 1600), Budapest, Hungary
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT06483334
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron-Oncology ( Site 4767), Barcelona, Spain
🇺🇸University of California San Francisco HDFCCC ( Site 4044), San Francisco, California, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center ( Site 4011), Indianapolis, Indiana, United States
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 129
- Registration Number
- NCT06482112
- Locations
- 🇺🇸
Gastroenterology and Liver Institute ( Site 0263), Escondido, California, United States
🇺🇸Excel Medical Clinical Trials ( Site 0268), Boca Raton, Florida, United States
🇺🇸Neoclinical Research ( Site 0275), Hialeah, Florida, United States
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06469944
- Locations
- 🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona, United States
🇧🇷Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Rio Grande Do Norte, Brazil
🇩🇪Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 6807), Hamburg, Germany
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06465186
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0, Chandler, Arizona, United States
🇺🇸California Liver Research Institute ( Site 0113), Pasadena, California, United States
🇺🇸Velocity Clinical Research, Panorama City ( Site 0124), Van Nuys, California, United States